Comparison of aromatase inhibitor (letrozole) and immunomodulators (infliximab and etanercept) on the regression of endometriotic implants in a rat model

Seyit Temel Ceyhan, Ceyhan ST, Önder Öngürü, Onguru O, Onder Onguru, Ulaş Fidan, Ulas Fidan, Fidan U, Ide T, Tayfun İDE, Yaman H, Halil Yaman, Halıl Yaman, Selim Kılıç, Selim Kilic, Kilic S, İskender Başer, Iskender Baser, Baser I
European journal of obstetrics, gynecology, and reproductive biology · 2010 · vol. 154(1) , pp. 100–104 · doi:10.1016/j.ejogrb.2010.09.003 · PMID:21035240 · W2080665124
article OA: closed CC0 ⤵ 29 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-08 ⓘ

This study investigated the effects of letrozole, infliximab, and etanercept on endometriotic implant regression in rats, finding that letrozole was most effective.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

ObjectiveNovel treatment strategies are needed in the treatment of endometriosis due to limited success rates with the currently available options. As inflammatory and immunological mechanisms have been shown to be involved in the mechanism of the disease, new modalities are likely to emerge. We investigated the effects of infliximab (INF), etanercept (ETA) and letrozole on the regression of experimental endometriosis.Study designIn this experimental randomized trial, endometriosis was induced surgically in 44 adult female Sprague-Dawley rats. Establishment of implants was confirmed in 41 animals by a second operation on the 21st day. The rats were then randomly divided into four groups. Group I (n = 10) served as controls. Group II (n = 11) received letrozole (0.18 mg/kg, i.p.), group III (n = 10, i.p.) ETA (2.016 mg/kg, i.p.), and group IV (n = 10) INF (15.12 mg/kg, i.p.) for a second 21-day period. Endometriotic implant size along with peritoneal fluid VEGF level and immunoreactivity were determined before and after the treatment in each group.ResultsEndometriotic implant size reduced in all treatment groups. The effect of letrozole and ETA on implant size was similar but was significantly better than INF. Level of VEGF in peritoneal fluid did not change in any treatment group but post-treatment VEGF immunoreactivity was found significantly lower in the letrozole treated group.ConclusionsLetrozole and ETA caused a regression on the implant size in experimental endometriosis. The only group with decreased VEGF expression was letrozole.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Antibodies, Monoclonal Aromatase Inhibitors Endometriosis Immunoglobulin G Immunologic Factors Nitriles Receptors, Tumor Necrosis Factor Triazoles Animals Antibodies, Monoclonal Aromatase Inhibitors Ascitic Fluid Ascitic Fluid Disease Models, Animal Endometriosis Endometriosis Etanercept Female Immunoglobulin G Immunologic Factors

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (29)

Cited by (29)

Source provenance

europepmc
last seen: 2026-08-03T06:10:56.557307+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:17:00.782903+00:00
License: CC0 · commercial use OK